evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,615 questions · 1,673 findings · 190 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 278 · 16.6%GRADE not reported 85 · 5.1%Very low 328 · 19.6%Low 460 · 27.5%Moderate 402 · 24%High 120 · 7.2%

Mepolizumab 300 mg vs placebo

Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 750 mg vs placebo

Exacerbations · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in number of participants experiencing an exacerbation within 6 months compared with placebo (low certainty).

2 findings from 1 review

Mepolizumab 100 mg vs placebo

Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg probably leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review